Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

Drawing inferences from observational data with possible confounding Heart failure is increasing in prevalence and is a major cause of morbidity and mortality worldwide,1 with prevalence ranging from ...